Holen Sie sich die Stockscreener-App
11.89
0.25%
-0.03
Schlusskurs vom Vortag:
$11.92
Offen:
$12.25
24-Stunden-Volumen:
40,781
Relative Volume:
0.98
Marktkapitalisierung:
$22.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+4.94%
1M Leistung:
+56.65%
6M Leistung:
+129.09%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.35
$12.62
1-Wochen-Bereich:
$11.00
$13.25
52-Wochen-Spanne:
$2.90
$13.34
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Firmenname
Neuphoria Therapeutics Inc
Sektor
Branche
Telefon
781-439-5551
Adresse
100 SUMMIT DR, BURLINGTON
Vergleichen Sie NEUP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
11.89 | 22.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Bestätigt | Maxim Group | Buy |
| 2022-01-10 | Eingeleitet | Berenberg | Buy |
| 2022-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Eingeleitet | Evercore ISI | Outperform |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Neuphoria Therapeutics Inc Aktie (NEUP) Neueste Nachrichten
technical analysis overview for neuphoria therapeutics inc. stock2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
What data driven models say about Neuphoria Therapeutics Inc.’s futureJuly 2025 Patterns & Stock Market Timing Techniques - Newser
How to integrate Neuphoria Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Reliable Trade Execution Plans - Newser
What to do if you’re stuck in Neuphoria Therapeutics Inc.Share Buyback & AI Enhanced Market Trend Forecasts - Newser
How to build a dashboard for Neuphoria Therapeutics Inc. stockBull Run & Entry Point Confirmation Alerts - Newser
Will Neuphoria Therapeutics Inc. benefit from macro trendsWeekly Trend Report & AI Powered Market Entry Ideas - Newser
Statistical indicators supporting Neuphoria Therapeutics Inc.’s strength2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
Why is Neuphoria Therapeutics Inc. stock going upPortfolio Update Summary & Expert Approved Trade Ideas - خودرو بانک
Is Neuphoria Therapeutics Inc. being accumulated by smart moneyQuarterly Profit Report & Accurate Intraday Trading Signals - خودرو بانک
Can Neuphoria Therapeutics Inc. recover in the next quarterQuarterly Profit Report & Weekly Market Pulse Updates - Newser
Is Neuphoria Therapeutics Inc. affected by consumer sentimentJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - خودرو بانک
Neuphoria completes enrollment for phase 3 anxiety drug trial By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. outperform the marketWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Can momentum traders help lift Neuphoria Therapeutics Inc.IPO Watch & Safe Capital Preservation Plans - Newser
Analyzing recovery setups for Neuphoria Therapeutics Inc. investorsWeekly Profit Recap & Verified Momentum Watchlists - Newser
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder - MarketScreener
Is Neuphoria Therapeutics Inc. a stock for growth or value investors2025 Investor Takeaways & Capital Protection Trading Alerts - خودرو بانک
Neuphoria completes enrollment for phase 3 anxiety drug trial - Investing.com
Neuphoria Therapeutics achieves target enrollment in AFFIRM-1 Phase 3 trial for BNC-210. - AInvest
Neuphoria Therapeutics Completes Target Enrollment in Phase - GlobeNewswire
Neuphoria Therapeutics Achieves Target Enrollment in Phase 3 AFFIRM-1 Trial for BNC-210 in Social Anxiety Disorder. - AInvest
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) - GlobeNewswire Inc.
Using flow based indicators on Neuphoria Therapeutics Inc.Rate Cut & AI Optimized Trading Strategy Guides - Newser
Chart based exit strategy for Neuphoria Therapeutics Inc.July 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - Newser
Will Neuphoria Therapeutics Inc. continue its uptrend2025 Performance Recap & Verified Trade Idea Suggestions - Newser
Is Neuphoria Therapeutics Inc. attractive for institutional investorsJuly 2025 Trade Ideas & AI Forecasted Entry/Exit Points - خودرو بانک
Technical analysis overview for Neuphoria Therapeutics Inc. stock2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
Is it too late to sell Neuphoria Therapeutics Inc.July 2025 Patterns & Daily Technical Stock Forecast Reports - Newser
Can you recover from losses in Neuphoria Therapeutics Inc.Forecast Cut & Real-Time Volume Spike Alerts - Newser
What is the long term forecast for Neuphoria Therapeutics Inc. stockJuly 2025 Final Week & High Conviction Investment Ideas - خودرو بانک
Has Neuphoria Therapeutics Inc. formed a bullish divergenceEarnings Overview Report & Real-Time Buy Zone Alerts - Newser
How to forecast Neuphoria Therapeutics Inc. trends using time seriesEarnings Trend Report & Stepwise Trade Execution Plans - Newser
Sentiment analysis tools applied to Neuphoria Therapeutics Inc.July 2025 Retail & Safe Capital Investment Plans - Newser
Using portfolio simulators with Neuphoria Therapeutics Inc. included2025 Market Trends & Technical Confirmation Trade Alerts - Newser
Is Neuphoria Therapeutics Inc.’s ROIC above industry average2025 Historical Comparison & Technical Entry and Exit Alerts - خودرو بانک
Exit strategy if you’re trapped in Neuphoria Therapeutics Inc.Weekly Volume Report & Fast Entry and Exit Trade Plans - Newser
Will Neuphoria Therapeutics Inc. benefit from AI trendsPortfolio Return Report & Real-Time Buy Signal Notifications - خودرو بانک
Is Neuphoria Therapeutics Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Free Risk Controlled Daily Trade Plans - Newser
Published on: 2025-09-02 13:20:15 - خودرو بانک
Why Neuphoria Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Update & Safe Investment Capital Preservation Plans - 한국정경신문
Finanzdaten der Neuphoria Therapeutics Inc-Aktie (NEUP)
Es liegen keine Finanzdaten für Neuphoria Therapeutics Inc (NEUP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):